Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome.
BACKGROUND
Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome.


OBJECTIVE
The aim of this study was to review the preclinical and clinical data on fesoterodine.


METHODS
The study involved a search of the Medline database and the proceedings volumes of urological congresses.


CONCLUSIONS
Fesoterodine functions as an orally active prodrug that is converted to the active metabolite 5-hydroxymethyltolterodine by non-specific esterases. 5-Hydroxymethyltolterodine is a muscarinic receptor antagonist. Fesoterodine is primarily eliminated as inactive metabolites along with significant renal excretion as the unchanged active metabolite 5-hydroxymethyltolterodine. Fesoterodine is indicated for use at doses of 4 and 8 mg once daily. In clinical studies both doses of fesoterodine were consistently superior to placebo in improving the symptoms of overactive bladder syndrome, with 8 mg/day having significantly greater effects than 4 mg/day.
Michel
Martin C
MC
University of Amsterdam, Department of Pharmacology and Pharmacotherapy, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. m.c.michel@amc.nl
D001559:Benzhydryl Compounds / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D018727:Muscarinic Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D013577:Syndrome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D018727:Muscarinic Antagonists; C526675:fesoterodine